{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:30Z","timestamp":1707524190149},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,10]]},"DOI":"10.7759\/cureus.13260","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T15:40:10Z","timestamp":1612971610000},"source":"Crossref","is-referenced-by-count":1,"title":["Atypical Hemolytic Uremic Syndrome: Cancer-Induced or Chemotherapy-Induced?"],"prefix":"10.7759","author":[{"given":"Ashish","family":"Sethi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs279","article-title":"Thrombotic microangiopathy and associated renal disorders","volume":"27","author":"Barbour T","year":"2012","unstructured":"Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012, 27:2673-2685. 10.1093\/ndt\/gfs279","journal-title":"Nephrol Dial Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.060003831.x","article-title":"Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura","volume":"60","author":"Ruggenenti P","year":"2001","unstructured":"Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001, 60:831-846. 10.1046\/j.1523-1755.2001.060003831.x","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3088","article-title":"Drug-induced thrombotic microangiopathy caused by gemcitabine","volume":"10","author":"Hasan S A","year":"2018","unstructured":"Hasan S A, Jain A G, Naim H, Munaf A, Everett G. Drug-induced thrombotic microangiopathy caused by gemcitabine. Cureus. 2018, 10:e3088. 10.7759\/cureus.3088","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2016.649","article-title":"Cancer-associated thrombotic microangiopathy","volume":"10","author":"Govind Babu K","year":"2016","unstructured":"Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016, 10:649. 10.3332\/ecancer.2016.649","journal-title":"Ecancermedicalscience"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton JM","year":"2016","unstructured":"Morton JM, George JN. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J Oncol Pract. 2016, 12:523-530.  10.1200\/JOP.2016.012096","journal-title":"J Oncol Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.229287","article-title":"Atypical hemolytic uremic syndrome: laboratory characteristics, complement-amplifying conditions, renal biopsy, and genetic mutations","volume":"29","author":"Hossain MA","year":"2018","unstructured":"Hossain MA, Cheema A, Kalathil S, et al.. Atypical hemolytic uremic syndrome: laboratory characteristics, complement-amplifying conditions, renal biopsy, and genetic mutations. Saudi J Kidney Dis Transpl. 2018, 29:276-283. 10.4103\/1319-2442.229287","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung MC","year":"1999","unstructured":"Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999, 85:2023-2032. 10.1002\/(SICI)1097-0142(19990501)85:9&lt;2023::AID-CNCR21&gt;3.0.CO;2-2","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2004.11.016","article-title":"Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature [Article in French]","volume":"26","author":"Desram\u00e9 J","year":"2005","unstructured":"Desram\u00e9 J, Duvic C, Bredin C, et al.. Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature [Article in French]. Rev Med Interne. 2005, 26:179-188. 10.1016\/j.revmed.2004.11.016","journal-title":"Rev Med Interne"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2013.042","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani O","year":"2014","unstructured":"Al Ustwani O, Lohr J, Dy G, LeVea C, Connolly G, Arora P, Iyer R. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol. 2014, 5:30-33. 10.3978\/j.issn.2078-6891.2013.042","journal-title":"J Gastrointest Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma KL","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes DJAR, et al.. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019, 58:859-874. 10.1007\/s40262-019-00742-8","journal-title":"Clin Pharmacokinet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2924-y","article-title":"Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab","volume":"96","author":"Alashkar F","year":"2017","unstructured":"Alashkar F, Vance C, Herich-Terh\u00fcrne D, Preising N, D\u00fchrsen U, R\u00f6th A. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Ann Hematol. 2017, 96:589-596. 10.1007\/s00277-017-2924-y","journal-title":"Ann Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2990-5","article-title":"Eculizumab hepatotoxicity in pediatric aHUS","volume":"30","author":"Hayes W","year":"2015","unstructured":"Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol. 2015, 30:775-781. 10.1007\/s00467-014-2990-5","journal-title":"Pediatr Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2017.10.001","article-title":"Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome","volume":"38","author":"Oruc A","year":"2018","unstructured":"Oruc A, Ayar Y, Vuruskan BA, et al.. Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia. 2018, 38:448-450. 10.1016\/j.nefro.2017.10.001","journal-title":"Nefrologia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"7","author":"Kulasekararaj AG","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, et al..  Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019, 7:540-549. 10.1182\/blood-2018-09-876805","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"7","author":"Lee JW","year":"2019","unstructured":"Lee JW, de Fontbrune FS, Lee Lee LW, et al.. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.  Blood. 2019, 7:530-539. 10.1182\/blood-2018-09-876136","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/51368-atypical-hemolytic-uremic-syndrome-cancer-induced-or-chemotherapy-induced","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:27Z","timestamp":1707506967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/51368-atypical-hemolytic-uremic-syndrome-cancer-induced-or-chemotherapy-induced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.13260","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,10]]}}}